Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Utah Medical Products (UTMD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Utah Medical Products (UTMD) over the last 16 years, with Q3 2025 value amounting to $2.6 million.

  • Utah Medical Products' Net Income towards Common Stockholders fell 2615.77% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year decrease of 2383.01%. This contributed to the annual value of $13.5 million for FY2024, which is 1548.64% down from last year.
  • Latest data reveals that Utah Medical Products reported Net Income towards Common Stockholders of $2.6 million as of Q3 2025, which was down 2615.77% from $3.0 million recorded in Q2 2025.
  • Utah Medical Products' 5-year Net Income towards Common Stockholders high stood at $4.3 million for Q4 2023, and its period low was $2.6 million during Q3 2025.
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was $3.9 million (2023), whereas its average is $3.7 million.
  • As far as peak fluctuations go, Utah Medical Products' Net Income towards Common Stockholders soared by 16092.92% in 2021, and later tumbled by 3229.12% in 2024.
  • Over the past 5 years, Utah Medical Products' Net Income towards Common Stockholders (Quarter) stood at $4.1 million in 2021, then dropped by 0.56% to $4.1 million in 2022, then rose by 4.31% to $4.3 million in 2023, then tumbled by 32.29% to $2.9 million in 2024, then decreased by 9.34% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $3.0 million for Q2 2025, and $3.0 million during Q1 2025.